Combination therapy for liver cancer after immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) for people with advanced liver cancer that got worse after initial treatment with immunotherapy. The goal is to see if this 'rechallenge' approach can help control the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery.
- Your cancer has grown or spread while you were on a previous treatment that included an immune checkpoint inhibitor (a type of immunotherapy).
- You have at least one tumor that can be measured on a scan.
- You are expected to live at least 3 more months.
- You have not taken a JAK inhibitor (a type of targeted therapy) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
This trial tests a combination of two drugs, cadonilimab and regorafenib, for people with liver cancer that has worsened after treatment with camrelizumab and apatinib. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of targeted radiation, an immunotherapy drug (PD-L1 inhibitor), and an anti-VEGF drug to shrink tumors and improve outcomes for people with advanced hepatocellular carcinoma that cannot be surgically removed.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.